Background: T-cell response to vaccination is highly variable, making it difficult to predict vaccine efficacy from clinical trials. CD4+ T cell activation requires presentation of a pool of antigenic peptides to a diverse repertoire of T cell receptors via class II major histocompatibility complexes (MHCII) [1]. Human leukocyte antigen (HLA) molecules contain the peptide binding […]
